Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) EBIT Margin: 2019-2025

Historic EBIT Margin for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to -3,347.36%.

  • Kymera Therapeutics' EBIT Margin fell 141943.00% to -3,347.36% in Q3 2025 from the same period last year, while for Sep 2025 it was 139,604.62%, marking a year-over-year increase of 13983325.00%. This contributed to the annual value of -8,439.84% for FY2024, which is 822922.00% down from last year.
  • Per Kymera Therapeutics' latest filing, its EBIT Margin stood at -3,347.36% for Q3 2025, which was down 354.30% from -736.82% recorded in Q2 2025.
  • Kymera Therapeutics' 5-year EBIT Margin high stood at 220.77% for Q4 2024, and its period low was -3,347.36% during Q3 2025.
  • For the 3-year period, Kymera Therapeutics' EBIT Margin averaged around -807.91%, with its median value being -478.83% (2023).
  • Per our database at Business Quant, Kymera Therapeutics' EBIT Margin soared by 29,809bps in 2021 and then slumped by 141,943bps in 2025.
  • Over the past 5 years, Kymera Therapeutics' EBIT Margin (Quarterly) stood at -222.55% in 2021, then tumbled by 1,681bps to -239.36% in 2022, then soared by 19,903bps to -40.33% in 2023, then skyrocketed by 26,110bps to 220.77% in 2024, then slumped by 141,943bps to -3,347.36% in 2025.
  • Its EBIT Margin stands at -3,347.36% for Q3 2025, versus -736.82% for Q2 2025 and -336.77% for Q1 2025.